Febrile neutropenia treatment: filgrastim and pegfilgrastim.
Keywords:
Colony-Stimulating Factors TU, Filgrastim, Neutropenia, PegfilgrastimAbstract
Aim: The use of granulocyte colony-stimulating factors in the therapeutic setting of febrile neutropenia is still unknown with regard to the prophylaxis one. The aim of the present work was to collect the information about this therapeutic use found out in the studies performed since 2003.
Methods: Seven electronic databases were searched in May 2012. Eligibility included works published in English, French and Spanish from 2003 on. Studies that involved the therapeutic use of filgrastim or pegfilgrastim in chemotherapy-induced febrile neutropenia were sought. Reviews, meta-analysis and works published as abstracts were excluded. The search was completed by checking the reference lists from the selected studies.
Results: One of them was performed in a hospital in the Lebanon, another one in a British hospital, another was a multi-centre study in Spain and the last one was performed in Australia through an electronic survey made to cancer specialists. In the Lebanon study, 59 out of 137 granulocyte colony-stimulating factors treatment courses were performed in the therapeutic setting. In the LEARN study in Spain 29.7% patients treated with daily granulocyte colony-stimulating factors used them as treatment, so did 17.3% patients receiving pegfilgrastim. 9.7% treatments with filgrastim were therapeutic in the British hospital. Finally, in Australia 27% haematologist would use granulocyte colony-stimulating factors in case 1 (low risk of medical complications). 7% oncologists would use them in their low risk case of medical complications and 9% would use them in case 2 (higher risk). The mean duration of the therapy in the different studies ranged between 4.8 and 6 days. The most frequent adverse effect was bone pain.
Conclusions: The results from the present review showed that daily granulocyte colony-stimulating factors were used more than pegfilgrastim in the treatment setting, being the latter used very little and even considered an exception. Therapies were short and safe.
Downloads
References
Gerlier L, Lamotte M, Awada A et al. The use of chemotherapy regimens carrying a moderate or high risk of febrile neutropenia and the corresponding management of febrile neutropenia: an expert survey in breast cancer an non-Hodgkin’s lymphoma. BMC Cancer. 2010; 10:642.
National Comprehensive Cancer Network (NCCN). Clinical Practice Guidelines in Oncology. Myeloid Growth Factors. v 1.2011. [En línea]. Disponible en: http://www.nccn.org
Heuser M, Ganser A, Bokemeyer C. Use of colony-stimulating factors for chemotherapy-associated neutropenia: review of current guidelines. Semin Hematol. 2007;44(3):148-156.
Lyman GH, Michels SL, Reynolds MW, Barron R, Tomic KS, Yu J. Risk of mortality in patients with cancer who experience febrile neutropenia. Cancer. 2010;116(23):5555-5563.
Schwartzberg LS. Neutropenia: etiology and pathogenesis. Clin Cornerstone. 2006; 8 (Suppl 5):S5-S11.
National Comprehensive Cancer Network (NCCN). Clinical Practice Guidelines in Oncology. Prevention and Treatment of Cancer-Related Infections v 2.2011. [En línea]. Disponible en: http://www.nccn.org
Smith TJ, Khatcheressian J, Lyman GH et al. American Society of Clinical Oncology (ASCO). 2006 Update Recommendations for the Use of White Blood Cell Growth Factors: An Evidence-Based Clinical Practice Guideline. J Clin Oncol. 2006; 24(19):3187-3205.
Aapro MS, Bohlius J, Cameron DA et al. 2010 Update of EORTC guidelines for the use of granulocyte colony-stimulating factor to reduce the incidence of chemotherapy-induced neutropenia in adult patients with lymphoproliferative disorders and solid tumors. Eur J Cancer. 2011; 47(1):8-32.
Krämer I. Recombinant G-CSF products and what pharmacists need to know. EJHP Practice. 2011; 17(5):36-45.
Crawford J, Caserta C, Roila F. ESMO Guidelines Working Group. Hematopoietic growth factors: ESMO clinical practice guidelines for the applications. Ann Oncol. 2010; 21 (Suppl 5):v248-251.
Pérez Velasco R. Review of granulocyte colony-stimulating factors in the treatment of established febrile neutropenia. J Oncol Pharm Pract. 2011; 17(3):225-232.
Clark OAC, Lyman GH, Castro AA, Clark LGO, Djulbegovic B. Colony-stimulating factors for chemotherapy-induced febrile neutropenia: A meta-analysis of randomized controlled trials. J Clin Oncol. 2005; 23(18):4198-4214.
Saab YB, Sharaf L, Zeidan I, Bizri A. Filgrastim use: evaluation in cancer and critically ill non-cancer patients. Cancer Therapy. 2003; 1:191-196.
Ozer H, Armitage JO, Bennett CL et al. 2000 Update of recommendations for the use of hematopoietic colony-stimulating factors: evidence-based, clinical practice guidelines. J Clin Oncol. 2000; 18:3558-3585.
Almenar D, Mayans J, Juan O et al. Pegfilgrastim and daily granulocyte colony-stimulating factor: patterns of use and neutropenia-related outcomes in cancer patients in Spain -results of the LEARN study. Eur J Cancer Care (Engl). 2009; 18(3):280-286.
Pérez Velasco R. Granulocyte colony-stimulating factor use in a large British hospital: comparison with published experience. Pharmacy Practice 2010; 8: 213-219.
Lingaratnam S, Slavin MA, Mileshkin L, Solomon B, Burbury K, Seymur JF et al. An australian survey of clinical practices in management of neutropenic fever in adult cancer patients 2009. Intern Med J. 2011; 41(1b):110-20.
Downloads
Published
How to Cite
Issue
Section
License
The articles, which are published in this journal, are subject to the following terms in relation to the rights of patrimonial or exploitation:
- The authors will keep their copyright and guarantee to the journal the right of first publication of their work, which will be distributed with a Creative Commons BY-NC-SA 4.0 license that allows third parties to reuse the work whenever its author, quote the original source and do not make commercial use of it.
b. The authors may adopt other non-exclusive licensing agreements for the distribution of the published version of the work (e.g., deposit it in an institutional telematic file or publish it in a monographic volume) provided that the original source of its publication is indicated.
c. Authors are allowed and advised to disseminate their work through the Internet (e.g. in institutional repositories or on their website) before and during the submission process, which can produce interesting exchanges and increase citations of the published work. (See The effect of open access).
